December 13, 2024
GENinCode partners with Genesupport SA for the ROCA® Test in Switzerland
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (“CVD”) and risk of ovarian cancer (“OC”), announces its partnership with Genesupport SA, part of the Sonic Switzerland network of laboratories, to enable country-wide access to the ROCA® Test.
November 2, 2022
Ovarian cancer surveillance in women with faulty BRCA genes results in earlier stage diagnosis for those deferring preventive surgery
Regularly monitoring women with faulty BRCA genes that make them highly susceptible to ovarian cancer, results in earlier stage* diagnosis in those who want to defer preventive surgery, finds research published online in the Journal of Medical Genetics.
November 2, 2022
The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 | Journal of Medical Genetics (bmj.com)
A pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2
November 2, 2022
Monitoring for ovarian cancer in high-risk women is beneficial, Cancer Alliance funded research shows – North Central London Cancer Alliance (nclcanceralliance.nhs.uk)
Research published in the latest issue of the Journal of Medical Genetics concludes that regularly monitoring women who carry BRCA gene alterations does provide some benefits.
November 2, 2022
UCLH research shows monitoring for ovarian cancer in high-risk women is beneficial : University College London Hospitals NHS Foundation Trust
UCLH research shows monitoring for ovarian cancer in high-risk women is beneficial : University College London Hospitals NHS Foundation Trust
November 2, 2022
